Apotex Inc. v. Wellcome Foundation Ltd.

Apotex Inc. v. Wellcome Foundation Ltd., [2002] 4 S.C.R. 153 is a leading Supreme Court of Canada decision on the requirement a patent in Canada. The Court rejected a challenge by the generic drug manufacturers Novopharm and Apotex to declare Glaxo Wellcome's patent for AZT, an AIDS-fighting drug, invalid.

Additional recommended knowledge

How to quickly check pipettes?

Daily Sensitivity Test

Essential Laboratory Skills Guide

The generic manufacturers claimed that the patent did not satisfy the utility requirement. Justice Binne, for the Court, considered the doctrine of sound prediction to determine whether the invention was useful on the day that it was filed. There are three elements. First, there must be a factual basis for the prediction at the date that it was filed. Second, the inventor must have a sound line of reasoning from which the desired result can be inferred from the factual basis. Third, there must be proper disclosure. Binnie found that all three requirements were satisfied.

See also

• List of Supreme Court of Canada cases (McLachlin Court)